<DOC>
	<DOCNO>NCT01051362</DOCNO>
	<brief_summary>This Phase II study explore efficacy toxicity Pegylated liposomal doxorubicin Carboplatin patient previously untreated non-small cell lung cancer ( NSCLC ) amenable radiotherapy surgical treatment . The planned enrollment trial 48 patient ( include 10 % rate inevaluable patient ) .</brief_summary>
	<brief_title>Pegylated Liposomal Doxorubicin Carboplatin First Line Treatment Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Pegylated liposomal doxorubicin ( PLD ) first antineoplastic drug derive new technology liposome formulation introduce clinical practice . The low myocardium uptake formulation account reduce cardiac toxicity , confirm preclinical model human . Preclinical data show activity NSCLC xenograft . This Phase II study explore efficacy toxicity Pegylated liposomal doxorubicin Carboplatin patient previously untreated non-small cell lung cancer ( NSCLC ) amenable radiotherapy surgical treatment .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologically confirm nonsmallcell bronchogenic carcinoma ( squamous carcinoma , adenocarcinoma , large cell carcinoma ) . Cytologic specimen obtain brushing , washing , needle aspiration define lesion acceptable . Mixed tumor smallcell anaplastic element eligible . Patients newly diagnose unresectable stage III IV disease eligible . Patients stage III disease ineligible combine modality therapy ( i.e. , pleural effusion , pericardial effusion , etc. ) . Patients must receive prior antineoplastic chemotherapy metastatic lung cancer prior study entry . Patients previous radiotherapy definitive therapy locally advance nonsmallcell eligible long recurrence outside original radiation port . Radiation therapy must complete great 4 week prior registration . Male female patient &gt; =18 year age . Life expectancy least 3 month . ECOG performance status &lt; =2 . Measurable disease RECIST criterion . Laboratory value follow : ANC &gt; =1500/mm3 ( 7 day prior treatment ) ; Hemoglobin &gt; =8 g/dL ; Platelets &gt; =100,000 mm3 ( 7 day prior treatment ) ; Bilirubin &lt; =1 x ULN institution ; AST/SGOT &lt; =2.5 x ULN &lt; =5.0 x ULN patient liver metastasis ALT/SGPT &lt; =2.5 x ULN &lt; =5.0 x ULN patient liver metastasis ; Creatinine &lt; =2.0 mg/dL Calculated ( measure ) GFR &gt; =40 mL/min ; PT/INR PTT &lt; =1.5 x ULN Peripheral neuropathy &lt; = grade 1 . Women childbearing potential must negative serum urine pregnancy test perform within 7 day prior start treatment . Patient must accessible treatment followup . All patient must able understand nature study give write informed consent prior study entry . A history cardiac disease define malignant hypertension , unstable angina , congestive heart failure &gt; grade 2 per New York Heart Association ( NYHA ) criterion , myocardial infarction within previous 6 month , symptomatic cardiac arrhythmia . Metastatic brain meningeal tumor . Uncontrolled intercurrent illness . Chemotherapy , investigational drug therapy , major surgery â‰¤ 4 week prior start study drug , patient recover side effect previous therapy . Patient &lt; =5 year free another primary malignancy , except primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow . Concomitant use anticancer therapy radiation therapy . Other concurrent severe , uncontrolled infection intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>Advanced Non-small Cell Lung Cancer</keyword>
	<keyword>Pegylated liposomal doxorubicin</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>